Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL DECANOATE versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL DECANOATE versus TARACTAN.
HALOPERIDOL DECANOATE vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol decanoate is a long-acting ester prodrug of haloperidol, a typical antipsychotic. Haloperidol acts primarily as a dopamine D2 receptor antagonist in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits affinity for D1, D3, D4, sigma, and 5-HT2 receptors, but its antipsychotic efficacy is primarily attributed to D2 blockade.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
100-200 mg intramuscular deep injection every 4 weeks. Maximum 450 mg per month.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life of haloperidol decanoate: approximately 3 weeks (range 14-28 days) due to slow release from depot and subsequent de-esterification. Steady-state achieved after 3-4 monthly doses.
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Renal: 40% (as metabolites; <1% unchanged); Fecal: 60% (primarily via biliary elimination).
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic